NYSE:WST - West Pharmaceutical Services Stock Price, Price Target & More

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services declared a quarterly dividend on Friday, May 4th. Investors of record on Wednesday, July 18th will be given a dividend of $0.14 per share on Wednesday, August 1st. This represents a $0.56 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 17th. View West Pharmaceutical Services' Dividend History.

West Pharmaceutical Services declared that its Board of Directors has approved a stock buyback program on Thursday, February 15th 2018, which authorizes the company to buyback 800,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its shares are undervalued.

West Pharmaceutical Services Inc. (NYSE:WST) posted its quarterly earnings data on Thursday, April, 26th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.64 by $0.02. The medical instruments supplier earned $415.70 million during the quarter, compared to analysts' expectations of $403.87 million. West Pharmaceutical Services had a net margin of 8.20% and a return on equity of 14.40%. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 EPS. View West Pharmaceutical Services' Earnings History.

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for West Pharmaceutical Services.

West Pharmaceutical Services issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $2.80 to $2.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.82. The company issued revenue guidance of $1.72 billion to $1.73 billion, compared to the consensus revenue estimate of $1.72 billion.

5 analysts have issued 1-year target prices for West Pharmaceutical Services' shares. Their forecasts range from $85.00 to $115.00. On average, they anticipate West Pharmaceutical Services' stock price to reach $104.20 in the next year. This suggests a possible upside of 5.4% from the stock's current price. View Analyst Ratings for West Pharmaceutical Services.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to West Pharmaceutical Services include Eisai (ESALY), OTSUKA HOLDINGS/ADR (OTSKY), McKesson (MCK), Centene (CNC), Amadeus It Group (AMS), Fresenius Medical Care AG & Co. KGaA (FME), Essilor International Cmgn Gnl D Optq (EI), Teva Pharmaceutical Industries (TEVA), Zimmer Biomet (ZBH), TERUMO Corp/ADR (TRUMY), LONZA Grp AG/ADR (LZAGY), Sunny Optical Technology (Group) (SNPTF), IDEXX Laboratories (IDXX), COLOPLAST A/S/ADR (CLPBY) and Cerner (CERN).

News headlines about WST stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. West Pharmaceutical Services earned a news sentiment score of 0.20 on Accern's scale. They also gave news headlines about the medical instruments supplier an impact score of 46.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

West Pharmaceutical Services' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (1.33%), Riverbridge Partners LLC (0.64%), Retirement Systems of Alabama (0.17%), Xact Kapitalforvaltning AB (0.02%), State of Alaska Department of Revenue (0.01%) and Bank of Montreal Can (0.01%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner, Paula A Johnson and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

WST stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Retirement Systems of Alabama and Fisher Asset Management LLC. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Daniel Malone and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.

WST stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Xact Kapitalforvaltning AB and State of Alaska Department of Revenue. View Insider Buying and Selling for West Pharmaceutical Services.

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WST stock can currently be purchased for approximately $98.87.

West Pharmaceutical Services has a market capitalization of $7.24 billion and generates $1.60 billion in revenue each year. The medical instruments supplier earns $150.70 million in net income (profit) each year or $2.78 on an earnings per share basis. West Pharmaceutical Services employs 7,500 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]